Risuteganib—a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risuteganib—a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-7
Publisher
Informa UK Limited
Online
2020-04-30
DOI
10.1080/13543784.2020.1763953
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abicipar pegol—a novel anti-VEGF therapy with a long duration of action
- (2019) Elad Moisseiev et al. EYE
- Emerging Concepts in the Treatment of Diabetic Retinopathy
- (2019) Michael Patrick Ellis et al. Current Diabetes Reports
- Ocular Distribution and Pharmacodynamics of SF0166, a Topically Administeredαvβ3Integrin Antagonist, for the Treatment of Retinal Diseases
- (2018) Ben C. Askew et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: A systematic review of real-world studies
- (2018) Claudio Bucolo et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Genetics of age-related macular degeneration (AMD)
- (2017) Margaret M. DeAngelis et al. HUMAN MOLECULAR GENETICS
- Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial
- (2017) Pravin U. Dugel et al. OPHTHALMOLOGY
- Diabetic macular edema, retinopathy and age-related macular degeneration as inflammatory conditions
- (2016) Undurti N. Das Archives of Medical Science
- Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema
- (2016) Peter A. Campochiaro et al. Current Diabetes Reports
- Distinct Effects of Integrins α X β 2 and α M β 2 on Leukocyte Subpopulations during Inflammation and Antimicrobial Responses
- (2016) Samir Jawhara et al. INFECTION AND IMMUNITY
- Integrin-based therapeutics: biological basis, clinical use and new drugs
- (2016) Klaus Ley et al. NATURE REVIEWS DRUG DISCOVERY
- Diabetic Macular Edema Diagnosis and Treatment in the Real World: An Analysis of Medicare Claims Data (2008 to 2010)
- (2016) Pravin U. Dugel et al. Ophthalmic Surgery Lasers & Imaging Retina
- Current therapeutic developments in atrophic age-related macular degeneration
- (2015) Jakub Hanus et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA
- (2015) Yit Yang et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema
- (2014) David S. Boyer et al. OPHTHALMOLOGY
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
- (2014) Wan Ling Wong et al. Lancet Global Health
- Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular Edema
- (2012) Peter A. Campochiaro et al. OPHTHALMOLOGY
- Inflammation and Age-Related Macular Degeneration (AMD)
- (2011) David G. Telander Seminars in Ophthalmology
- Transforming growth factor-β-induced gene product, as a novel ligand of integrin αMβ2, promotes monocytes adhesion, migration and chemotaxis
- (2007) Ha-Jeong Kim et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation